Effect of systemic administration of AEE788 on lung tumors derived from TGF-α–transfected or vector-transfected PC14-PE6 cells growing orthotopically in the lungs of nude mice
| Group . | Lung tumor . | . | . | Pleural effusion (incidence) . | Metastasis to lymph node (incidence) . | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| . | Body weight (g), median (range) . | Incidence . | Weight (g), median (range) . | . | . | |||||
| PC14-PE6/Neo | ||||||||||
| Vehicle | 28.5 (22.6-33.2) | 9/9 | 0.11 (0.01-0.43) | 5/9 | 2/9 | |||||
| AEE788 | 28.3 (19.9-32.3) | 9/9 | 0.11 (0.01-0.51) | 3/9 | 1/9 | |||||
| PC14-PE6/TGF-α | ||||||||||
| Vehicle | 28.3 (24.0-31.5) | 9/9 | 0.31 (0.06-0.85) | 6/9 | 2/9 | |||||
| AEE788 | 27.8 (24.1-31.1) | 9/9 | 0.16 (0.01-0.25)* | 1/9* | 1/9 | |||||
| Group . | Lung tumor . | . | . | Pleural effusion (incidence) . | Metastasis to lymph node (incidence) . | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| . | Body weight (g), median (range) . | Incidence . | Weight (g), median (range) . | . | . | |||||
| PC14-PE6/Neo | ||||||||||
| Vehicle | 28.5 (22.6-33.2) | 9/9 | 0.11 (0.01-0.43) | 5/9 | 2/9 | |||||
| AEE788 | 28.3 (19.9-32.3) | 9/9 | 0.11 (0.01-0.51) | 3/9 | 1/9 | |||||
| PC14-PE6/TGF-α | ||||||||||
| Vehicle | 28.3 (24.0-31.5) | 9/9 | 0.31 (0.06-0.85) | 6/9 | 2/9 | |||||
| AEE788 | 27.8 (24.1-31.1) | 9/9 | 0.16 (0.01-0.25)* | 1/9* | 1/9 | |||||
NOTE: PC14-PE6/Neo or PC14-PE6/TGF-α cells (2.5 × 105) were injected into the left lobe of the lung. Treatment with AEE788 (50 mg/kg orally thrice weekly) or vehicle control was initiated 5 d after tumor injection. All mice were killed and tumors were harvested 30 days after tumor injection when mice in the control group became moribund. Lung tumor weight was determined by subtracting the normal lung weight (0.17 g) from the weight of the tumor-containing lung.
P < 0.05, compared with vehicle control tumors according to the χ2 test (for incidence) and Student's two-tailed t test.